KDR and lung cancer: Based on the endothelial cell tropism of LNP-CAD9, we further investigated the therapeutic potential of this platform in an orthotopic lung cancer model, through CRISPR-Cas9 gene editor-mediated in vivo gene editing of VEGFR2 in lung endothelial cells for antiangiogenic cancer therapy.